Drugs / MM09
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05641272 | Nov 2023 → Jun 2026 overdue | allergic asthma, allergic rhinitis | Inmunotek S.L. | Not yet recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07348302 | Apr 2025 → Apr 2029 expected | rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
| Phase 3 | NCT05400811 | Dec 2022 → Jul 2024 | allergic asthma, house allergic alveolitis, perennial allergic rhinitis | Inmunotek S.L. | Unknown | No outcome recorded |
| Phase 3 | NCT04874714 | Apr 2021 → Oct 2023 | perennial allergic rhinitis | Inmunotek S.L. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04435990 | Oct 2020 → Dec 2026 expected | allergic asthma, allergic rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-05-19 | Inmunotek S.L. | Results Alergoides-manano: primeros resultados clínicos en fase 2 inmunotek.com ↗
Los resultados demuestran un efecto dosis-respuesta con diferencias significativas sobre el placebo y un excelente perfil de seguridad, tanto en administración subcutánea como sublingual. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-05-19 | Inmunotek S.L. | Alergoides-manano: primeros resultados clínicos en fase 2 inmunotek.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM09 | “Sublingual MM09 is being investigated as an etiological treatment for moderate-to-severe allergic rhinitis and/or rhinoconjunctivitis” NCT07348302 ↗ |
| Modality | Other / unclassified | “Purified allergenic extract” NCT04435990 ↗ |
| Route | Subcutaneous | “subcutaneous immunotherapy” NCT04435990 ↗ |